10.22.18

Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors

Source: Orasis Pharmaceuticals

Orasis Pharmaceuticals announced the appointment of Jeffry Weinhuff as chairman of the board of directors. As a managing partner of Visionary Ventures, Mr. Weinhuff joins the Orasis board of directors in conjunction with the recent Series B financing led by Visionary Ventures, a venture capital fund exclusively focused on investing in the most promising ophthalmology companies.

“I am honored to be appointed chairman of the board at Orasis,” Mr. Weinhuff said in a company news release. “CSF-1 has demonstrated tremendous potential to restore near vision and improve the quality of life for people with presbyopia by providing a meaningful alternative to the cumbersome and invasive existing treatment options. The executive team of Orasis has decades of experience and expertise in the ophthalmology field, and I look forward to working closely with them to advance the development of CSF-1.”

“The appointment of Mr. Weinhuff, along with the recent Series B financing led by Visionary Ventures, provides strong validation for our approach,” Elad Kedar, chief executive officer of Orasis, said in the news release. “Mr. Weinhuff brings a wealth of experience to the Orasis board of directors. We are confident that his depth of experience in the field of ophthalmology will ensure the company’s continued success as we advance in our mission to provide a pharmacological alternative to reading glasses for more than 1.8 billion people worldwide who currently suffer from presbyopia.”

Mr. Weinhuff has been active in the private equity realm for over 30 years and is the managing partner of Visionary Venture Fund, a later-stage venture fund focused on investing in drugs and devices for the eye. Visionary employs a unique approach to venture investing by partnering with over 40 key opinion leader (KOL) ophthalmologists, as well as other sophisticated investors and industry professionals. In Visionary’s nine portfolio companies, the combination of KOL insights and a professional investment approach reduces risk and enhances predictable returns.

Located in Orange County, California, Visionary works closely with senior eye care professionals to lead investments in the fast-growing $40 billion ophthalmology industry. 

 

Related Content